+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Impact on Inovio Pharmaceuticals Inc.


This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

  • The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
  • Inovio’s pipeline is most active in early-stage drug development
  • INO-4800 is Inovio’s COVID-19 vaccine
  • Funding from different sources for INO-4800

Reasons to Buy
  • An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.

Table of Contents

1 Executive Summary
2 Company Overview
2.1 Key Stats
2.2 SWOT Analysis
2.3 Sales Forecast Overview
3 Regional Analysis
3.1 COVID-19 Spread vs. Location of Inovio Pharmaceuticals Inc. Trials
3.2 COVID-19 vs. Non-COVID-19 Trials
4 Reaction to COVID-19
4.1 INO-4800
4.2 Insight’s Exclusive Intel: Inovio Pharmaceuticals
4.3 Global Analyst Consensus Sales Forecast
4.4 Upcoming Events
4.5 Recent Deal Activity
5 Key Findings
6 Appendix
6.1 Methodology
6.2 About the Publisher
6.3 Contacts

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Inovio Pharmaceuticals Inc.